DPTX3186 in Wnt Pathway Activated Solid Tumors

Inclusion Criteria:

* Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available.
* At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI.
* ECOG performance status of 0 or 1.
* Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy.
* Age ≥18 years (or ≥ age of majority per local regulation)
* Life expectancy ≥3 months
* Willing and able to comply with protocol requirements

Exclusion Criteria:

* Symptomatic or uncontrolled brain metastasis requiring concurrent treatment,
* Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.).
* Inadequate organ function
* Known hypersensitivity to study drug or excipients